The Innovative Medicines Initiative moves translational immunology forward

The Innovative Medicines Initiative moves translational immunology forward

The Innovative Medicines Initiative (IMI) was established in 2008 as a public‐private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of immunology 2013-02, Vol.43 (2), p.298-302
Hauptverfasser: Goldman, Michel, Wittelsberger, Angela, De Magistris, Maria‐Teresa
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Animals
Cooperative Behavior
Drug Industry
Humans
Public-Private Sector Partnerships
Translational Medical Research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The Innovative Medicines Initiative (IMI) was established in 2008 as a public‐private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on the concept of pre‐competitive research. Several consortia supported by IMI are dedicated to immuno‐inflammatory disorders, immune‐based biopharmaceuticals and vaccines. Herein, we present the key principles underlying IMI, briefly review the status of projects related to translational immunology, and present future topics of interest to immunologists.
ISSN:0014-2980
1521-4141
DOI:10.1002/eji.201370024